ClinicalTrials.gg

Program

KRAS G12C Inhibitor JMKX001899

Its studies are mostly in Carcinoma, Non-Small-Cell Lung, led by Jemincare.

Furthest: phase 3, since Nov 17, 20253 company-led studies, 3 open or runningNext primary completion: Dec 31, 2027 (phase 3)

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
Jemincare33 open or runningphase 3since Nov 17, 2025Mar 21, 2024Dec 31, 2027phase 3 · NCT07242274

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

  1. Mar 21, 2024First study: phase 1 study in Solid Tumor, AdultFirst studyNCT06348290 · 72 planned
  2. Jun 19, 2024Phase 1 study in Solid Tumor, AdultNCT06473948 · 27 planned
  3. Nov 17, 2025Phase 3 study in Carcinoma, Non-Small-Cell LungPhase 3 reachedNCT07242274 · 472 planned · China

Ahead

  1. Dec 31, 2027Primary completion: phase 3 study in Carcinoma, Non-Small-Cell LungNCT07242274

TargetBeta

KRAS →read by rule
“An orally bioavailable inhibitor of the oncogenic KRAS substitution mutation G12C, ”NCIt, by rule

Other programs on KRAS

ProgramCompanyFurthest phaseStudies
sotorasibruleAmgenphase 328
adagrasibruleBristol-Myers Squibbphase 316
olomorasibEli Lillyphase 316
divarasibHoffmann-La Rochephase 313
KRAS G12D Inhibitor VS-7375ruleGenfleet Therapeutics (Shanghai)phase 312
glecirasibruleAllist Pharmaceuticalsphase 312
calderasibMerckphase 312
daraxonrasibruleRevolution Medicinesphase 310
garsorasibruleInventisBiophase 38
KRAS G12D Inhibitor HRS-4642Jiangsu HengRui Medicinephase 37
zoldonrasibruleRevolution Medicinesphase 36
HRS-7058Jiangsu HengRui Medicinephase 36

Studies

All 3 led by companies developing it, newest first. Each opens its study page.

StudyPhaseStatusPrimary completionSize
NCT07242274Carcinoma, Non-Small-Cell Lung · China3Not yet recruitingDec 31, 2027472
NCT06473948Solid Tumor, Adult1Not yet recruitingSep 24, 202427
NCT06348290Solid Tumor, Adult1Not yet recruitingMay 31, 202472

How it is read

Names in the registry

  • “JMKX001899”, 5 entries

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.